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Abstract
Purpose—Resistance to cisplatin-based chemotherapy is a major obstacle to bladder cancer
treatment. We aimed to identify microRNAs that are dysregulated in cisplatin-resistant disease,
ascertain how these contribute to a drug resistant phenotype and how this resistance might be
overcome.
Experimental Design—MicroRNA expression in paired cisplatin resistant and sensitive cell
lines was measured. Dysregulated microRNAs were further studied for their ability to mediate
resistance. The nature of the cisplatin resistant phenotype was established by measurement of
cisplatin/DNA adducts and intracellular glutathione. Candidate microRNAs were examined for
their ability to (i) mediate resistance and (ii) alter the expression of a candidate target protein
(SLC7A11); direct regulation of SLC7A11 was confirmed using a luciferase assay. SLC7A11
protein and mRNA, and microRNA-27a were quantified in patient tumour material.
Results—A panel of microRNAs were found to be dysregulated in cisplatin resistant cells.
MicroRNA-27a was found to target the cystine/glutamate exchanger SLC7A11 and to contribute
to cisplatin resistance through modulation of glutathione biosynthesis. In patients, SLC7A11
expression was inversely related to microRNA-27a expression, and those tumors with high mRNA
expression or high membrane staining for SLC7A11 experienced poorer clinical outcomes.
Resistant cell lines were resensitized by restoring microRNA-27a expression, or reducing
SLC7A11 activity with an siRNA or with sulfasalazine.
Conclusion—Our findings indicate that microRNA-27a negatively regulates SLC7A11 in
cisplatin-resistant bladder cancer, and shows promise as a marker for patients likely to benefit
from cisplatin-based chemotherapy. SLC7A11 inhibition with sulfasalazine may be a promising
therapeutic approach to the treatment of cisplatin-resistant disease.
INTRODUCTION
Around 7.6 million individuals die from cancer annually (1). Despite recent advances, the
prognosis for advanced tumors remains poor. One of the front line treatments for bladder
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cancer is cisplatin-based combination chemotherapy, but the effectiveness of this treatment
is severely limited through the development of cisplatin resistance. Most patients with
advanced bladder cancer typically show a good initial response to treatment, but ultimately
90% of these patients will suffer a recurrence of cisplatin resistant disease (2) In solid
tumors, methods to lower cisplatin concentration within cells, such as increased drug efflux,
reduced influx or sequestration appear to be amongst the predominant mechanisms of
resistance. The latter may be achieved by a variety of compounds, including glutathione
(GSH). This thiol-containing tripeptide is synthesized by nearly all cells, it is a strong
electron donor and protects against the harmful effects of various endogenous stresses by
quenching reactive hydroxyl free radicals, other oxygen-centered free radicals, and radical
centers on DNA and other biomolecules (3). In this way GSH is also able to protect cells
from the cytotoxic effects of various chemotherapeutics, including cisplatin (4), and
radiotherapy. A rate limiting step in GSH synthesis is the availability of cystine (5), which
provides the cysteine moiety of glutathione. Cystine import is carried out by the
hetrodimeric xc- cystine-glutamate transporter (6), which is comprised of SLC3A2 (also
known as 4F2HC) and SLC7A11 (also known as xCT). Upregulation of SLC7A11 has been
reported as a mechanism of cisplatin resistance in ovarian cancer (7).
Resistance to cisplatin treatment in bladder cancer is common, and can be mediated through
one of more of a large number of pathways (8). The changes in protein expression that
underpin these pathways may arise through genetic or epigenetic means (8). The latter
include changes in DNA methylation and microRNA expression (9). These short single
stranded RNAs play key roles in many carcinogenic processes (10) and primarily act as
negative regulators of genes through the interaction with the 3′UTR of target mRNAs
resulting in either mRNA destruction or inhibition of translation (11). Alterations in
expression of particular microRNAs following the development of cisplatin resistance with
functional consequences for target mRNAs is well documented in various cancer cell lines
including those derived from breast (12) and ovarian cancers (13). Here we present evidence
that a change in expression of microRNA-27a contributes to cisplatin resistance in bladder
cancer through modulating the expression of the SLC7A11 and as a result, increasing levels
of intracellular glutathione. We demonstrate a way to reverse resistance that has clinical
potential and suggest that the biochemical consequences of this mechanism of resistance
may be used to stratify drug choice in patients with advanced cancer.
Materials and Methods
Cell lines, single cell clones and cisplatin-resistant variants
Cisplatin-resistant cell lines were generated from heterogeneous cells and sensitive single
cell clones using EJ/T24 and RT112 bladder cancer lines. Cells were grown in increasing
drug concentrations (10-20% increase per passage at 70% confluence) for 4 months. Primary
cells were purchased from ATCC and grown in DMEM with 10% fetal calf serum. The
adapted cell lines are deposited at the Health Protection Agency, UK. A2780-DDP cells
were obtained from Sigma, UK.
Clonogenic survival assay
500 – 2500 cells were plated in triplicate onto 100 mm dishes 4 hours prior to the addition of
increasing doses of cisplatin as indicated. Ten days later, when colonies could be observed,
they were fixed and stained with methylene blue in methanol (4 g/l). Colonies consisting of
more than 50 cells were subsequently counted. Each colony was assumed to represent one
cell surviving from the original number plated and the surviving fraction for each dose
calculated compared to untreated control. When siRNA depleted cells were used they were
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transfected as above for 48 hours, then replated in the presence or absence of increasing
doses of cisplatin.
Quantification of microRNA expression
Total RNA was extracted using the mirVana™ kit (Ambion, TX). The expression of 357
miRs was determined using rtPCR with microfluidic cards (Human microRNA v1.0,
Applied Biosystems, Warrington, UK) used as per manufacturers instructions and analysed
on an ABI 7900HT real time PCR system. Relative expression was calculated from the ΔCt
value for each microRNA, calculated by the subtraction of the plate mean Ct value from the
Ct value for each specific microRNA. ΔΔCt values between resistant and sensitive lines
were calculated, and used to generate fold changes in expression using the expression
2−ΔΔCt. Standalone taqman qPCR assays (Applied biosystems), used according to the
manufacturers instructions were also used to confirm downregulation of microRNA-27a in
resistant cells.
Measurement of cisplatin adducts in DNA
Cells were treated with cisplatin for 2 hours, harvested at relevant time points and frozen at
−80°C until analysis. Genomic DNA was extracted using a DNeasy kit (Qiagen), treated
with RNAse A (Sigma, UK) to remove cisplatin-damaged RNA. Exactly 1 μg DNA from
each sample was loaded into a dotblotter (Biorad, CA), washed thoroughly with 20x SSPE
buffer and baked (80°C, 30 mins). The DNA was then blocked with 5% milk and probed
using R-C18 monoclonal antibody (Oncolyse, Germany) raised against 1,2 [GG] intrastrand
adducts (14) and then with an HRP-conjugated anti-rat IgG (#7707 – NEB, US). Dots were
developed using a chemiluminescent substrate (GE Healthcare, UK), visualized and
quantified using a LAS-3000 imager (Fujifilm).
Expression of cisplatin transport and sequestration molecules
The expression of mRNAs important for cisplatin transport (ATP7A, ATP7B,
SLC31A1(CTR1)) and glutathione biosynthesis (SLC3A2(4F2HC), GCLC, GCLM, GSS,
GSR, SLC7A11(xCT)) was measured using real time PCR of cDNA generated by reverse
transcription of cellular RNA using random hexamers. Primers were validated using melting
curve analysis, and by inspection of an electrophoretic gel for a single band of the expected
size. mRNA quantification was normalized to the average of β -actin and U1 RNA
expression and fold changes in resistant cells calculated using from ΔΔCt values. The
expression of ATP7A, SLC31A1 and SLC7A11 proteins were measured using western
blotting using primary antibodies (SC-32900 and SC-66847 (Santa Cruz) and NB300-318
(Novus).
Cellular glutathione concentration
Levels of intracellular GSH were measured using a GSH-Glo ™ glutathione assay kit
(Promega, UK). In triplicate, 5000 cells were plated, left for 4hrs before measuring the
luminescence with a SpectraMax luminometer (Molecular Devices, US), according to
manufacturers instructions. Tris(2-carboxyethyl)phosphine (Thermo, UK) was added to
reduce oxidized GSH and ascertain the levels of total GSH present in each sample.
Restoration of underexpressed microRNA expression
To modulate miR expression, cells were transfected with Pre-miR™ miRNA precursors or
relevant scrambled negative control RNAs (Applied Biosystems, Warrington, UK) using
Lipofectamine™ RNAiMAX (Invitrogen, Carlsbad, CA). Six well plates were loaded with 5
pM Pre-miR in 500 μl serum-free medium to which 5 μl RNAiMAX was added 20 mins
before 100000 cells. Cells were used after 48-72 hrs and desired alteration of miR
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expression level was confirmed using a taqman microRNA qPCR (Applied Biosystems,
Warrington, UK).
Luciferase reporter assay
The first 1100 bp of the SLC7A11 3′UTR containing the microRNA-27a binding site with
was cloned from EJ-R/EJ mixed cDNA and ligated into pMIR REPORT (Invitrogen, UK).
The resulting pMIR REPORT + SLC7A11 3′UTR plasmid was subjected to a round of site
directed mutagenesis in order to introduce two mutations in to the microRNA-27a binding
site. Dual luciferase assays were conducted in a 6 well plate format., pMIR REPORT +
SLC7A11 3′UTR and pMIR REPORT + Mutated SLC7A11 3′UTR (100 ng) was
transfected into 70% confluent HEK293 cells, along with miScript microRNA-27a inhibitor,
or scrambled RNA control (50 pMol) (Applied Biosystems, UK) and pRL-TK renilla
luciferase plasmid (0.7 ng). 48 hours post transfection firefly and renilla luciferase were
quantified sequentially using the Dual Luciferase Assay kit (Promega, UK) and
luminescence was measured using the manufacturers recommended luminometer (Promega
Glomax). Firefly luciferase expression was quantified and normalized to Renilla luciferase
expression.
siRNA knockdown and small molecule inhibition of SLC7A11
SLC7A11 was knocked down using a commercially available ON-TARGET smartpool
RNA from Thermo Fisher, UK. Sulfasalazine was obtained from Sigma, UK. For
clonogenic assays cells were pre-treated for 48 hours with siRNA / sulfasalazine prior to re-
plating and treatment with cisplatin.
Patients and tumors
To evaluate cell culture findings in human bladder cancer, we examined the tumors from
354 patients in two separate cohorts (supplementary tables, S1, S2). The first cohort
included 139 primary tumors representing all disease phenotypes, collected prospectively
from the Royal Hallamshire Hospital, Sheffield. We microdissected sections of freshly
frozen tissue to enrich for tumor cells (>90%) and extracted total RNA, as above. The
second cohort included 215 patients treated with adjuvant chemotherapy for invasive
bladder cancer. Of these, the majority (n=149) were from a phase 3, multi-centre
randomized controlled trial conducted by the German Arbeitsgemeinschaft Urologische
Onkologie (AUO) comparing two adjuvant regimens (Cisplatin/Methotrexate vs.
Methotrexate/Vinblastine/Adriamycin/Cisplatin (AUO-AB 05/95)) (15). For each patient we
obtained archived FFPE tissue and extracted 3 × 1.5 mm cores (33-31A P/25, Miltex Inc,
York, PA, USA) from cancerous regions to construct a tissue microarray as detailed
elsewhere (16) (17). TMA content and construction were controlled by a certified
uropathologist (AH).
Tissue Array
Protein expression was determined using automated immunohistochemistry (programme:
SCC1, Benchmark XT, Ventana Medical Systems, Arizona). For SLC7A11 we used a
polyclonal antibody (xCT, Thermo-Scientific (Cat.-No. PA1-16893)) at 1:400 dilution for
30 min. Sections were visualized with diaminobenzidine (DAB) chromogen and
counterstained in a modified Mayer haematoxylin. Negative controls were performed using
normal serum rather than SLC7A11 antibody. Membranous staining was scored for intensity
and percentage of positive cells. High SLC7A11 expression was defined as strong intensity,
in 15% or more of cells.
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Statistical analyses
Associations between miR expression and cisplatin-sensitivity were tested using fold
changes in resistant and sensitive cells. We identified miRs that consistently showed more
than a two fold difference (either gain or loss) in expression between resistant and sensitive
cells, and selected those in which this reached statistical significance (defined as p<0.05,
Students T Test). We compared these with miR expression profiles in primary BC (18)
generated using the same array. Hierarchical clustering was performed using Cluster 3.0 and
visualized in Tree view (Eisen Lab). MicroRNAs that were differentially expressed in
resistant compared to sensitive cells, were used to hierarchically cluster samples according
to the cell line and presence/absence of chemoresistance Correlation between continuous
variables was assessed using Pearson’s correlation coefficient within SPSS. For patient
outcomes, we compared RNA and protein expression with tumor pathology and subsequent
phenotype. Associations between clinicopathological features and tumor behavior were
examined using univariable and stepwise multivariable Cox proportional hazards regression
models (SPSS Vsn. 14.0 (SPSS Inc. Illinois)). Outcomes with respect to time were plotted
using the Kaplan-Meier method and compared using a Log rank test within SPSS (Vsn. 19.0
SPSS Inc.). Tumor progression was defined as the presence of pathological, radiological or
clinical evidence of an increase in tumor stage and measured from the time of surgery to the
time of proven event. Where cisplatin sensitivity was compared between cell lines, or
between control cells and cells treated with a drug, precursor miRNA or siRNA statistical
significance was calculated using Student’s two tailed T test.
Results
microRNA expression is altered in cisplatin-resistant bladder cancer cells
To identify changes in microRNA expression associated with cisplatin resistance, we
compared matched cisplatin sensitive and resistant bladder cancer cell lines. The latter were
derived by culturing the bladder cancer cell line EJ, or single cell clones derived from the
original heterogeneous EJ (namely clones D4 and G7) in media augmented with increasing
cisplatin concentrations for several months. This resulted in three cisplatin resistant cell lines
(EJ-R, D4-R and G7-R) all of which were able to tolerate much higher concentrations of
cisplatin than any of the parental lines (Fig. 1A). IC50 concentrations for cisplatin were
typically <1 μM for sensitive lines and 10 μM for resistant lines. MicroRNA expression
profiling in these paired cell lines revealed that whilst the expression of the majority of
microRNAs remained unchanged (Fig. 1B), a microRNA signature could be identified that
stratified cisplatin resistance (Fig. 1C). A second set of paired cisplatin sensitive and
resistant bladder cancer cell lines, generated in the same way using RT112 cells as the
parental line (RT112 and RT112-R) were also included in this analysis, and displayed a
similar microRNA profile (Fig. 1C).
Cisplatin induces fewer 1,2 (G,G) Intrastrand adducts in resistant cells
Resistance to cisplatin can occur either prior to DNA adduct formation via changes in
cellular metabolism of cisplatin or post-adduct formation via changes in DNA damage
repair. To initially characterize the mechanism by which cisplatin resistance had arisen in
our cells, we measured cisplatin-induced 1,2 (G,G) intrastrand DNA crosslinks using
monoclonal antibodies directed against these adducts in EJ and EJ-R cells (14). Two hours
following treatment resistant cells displayed significantly fewer 1,2 (G,G) intrastrand
crosslinks compared with sensitive cells (Fig. 2A, p<0.001 for all concentrations of cisplatin
above 1 μM). When cisplatin was removed from growth media following a two hour
treatment of 12 μM, in both the sensitive and resistant cell lines adducts were repaired, as
evidenced by the reduction in the number of adducts in genomic DNA over the following 48
hours (Fig. 2B, 2C). The rate at which these adducts were removed appeared broadly similar
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between resistant and sensitive lines. This suggests a resistance mechanism related to
cisplatin influx/efflux or to cytoplasmic detoxification of cisplatin prior to the cytotoxic
interaction with DNA in the nucleus, rather than a difference in ability of resistant cells to
tolerate or repair cisplatin-induced DNA damage.
Cisplatin resistance is mediated through increased expression of SLC7A11 and increased
production of glutathione
The expression of copper transporter proteins are known to be responsible for the efflux
(ATP7A/ATP7B) (19) and influx (CTR1) (20) of cisplatin, and their dysregulation has been
linked with cisplatin resistance in some cancers, most notably ovarian (21). Initial analysis
of mRNA levels of these copper transporters revealed that ATP7B mRNA was significantly
downregulated by approximately 50% in the three resistant lines whereas ATP7A mRNA
was significantly upregulated by around 40% (Fig. 3A). Increased mRNA expression of the
cisplatin efflux protein ATP7A was not considered a likely candidate for the modulation of
cisplatin resistance however, as this increased mRNA expression was not accompanied by
an increase in protein levels as evidenced by western blot (Fig 3D). CTR1 mRNA was
typically threefold upregulated in all resistant cell lines when compared to corresponding
sensitive cell lines (Fig 3A). This is the opposite of what would be expected were these
influx and efflux proteins to be involved in the regulation of cisplatin resistance and, like
ATP7A, this altered mRNA expression was not reflected in levels of the CTR1 protein (Fig
3D). This suggests that changes in the cellular import and export of cisplatin are unlikely to
be responsible for the resistance of our bladder cancer cell lines to cisplatin. Following
import into cells cisplatin is able to form conjugates with glutathione leading to its
sequestration and detoxification(22), and increased glutathione levels have been observed in
other cisplatin-resistant cell lines (23). We found significantly increased concentrations of
both reduced (GSH) and oxidized (GSSG) glutathione in cisplatin resistant cells (Fig. 3B).
Resistant cells displayed levels of GSH and GSSG approximately double that of the
sensitive parental line, suggesting that increased glutathione production might be responsible
for cisplatin resistance. We examined mRNA expression of the six major genes whose
protein products are concerned with GSH biogenesis in paired sensitive and resistant cell
lines (Fig 3C). Many of these genes displayed a degree of small but significant upregulation
in resistant cells. However one gene, SLC7A11 was particularly significantly overexpressed
in resistant cells, displaying a tenfold increase in expression in resistant lines and a high
degree of statistical significance. We also examined the expression of SLC7A11 protein and
found it to be overexpressed in resistant cells (Fig 3D). SLC7A11 is one part of the
heterodimeric xc- cystine/glutamate exchanger, and as cystine bioavailability is a critical
factor in the rate of glutathione production it may represent the point at which the increased
rate of glutathione production in resistant cells is regulated. This suggests that changes in the
expression of genes involved in glutathione production, particularly SLC7A11 might be
responsible for resistance in our resistant cell lines.
Overexpression of microRNA 27a reduces levels of SLC7A11 and intracellular glutathione,
and resensitises resistant cells to cisplatin
To determine whether SLC7A11 was a candidate for regulation by microRNA, we examined
the 3′UTR for sites of potential microRNA interaction using TargetScan
(www.targetscan.org) and compared them to our expression profiles. Of the microRNAs
predicted to target the 3′UTR of SLC7A11, we observed microRNAs-25 and 27a were
significantly downregulated in our resistant lines and had appeared in our panel of
dysregulated miRs (Fig. 1C), in keeping with consequential upregulation of SLC7A11.
MicroRNA-32 was also shown to have the potential to interact with the 3′UTR of
SLC7A11, and while it did not appear in our signature of dysregulated miRs, it did show
consistent downregulation in all resistant cells compared with their sensitive parental lines.
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However transfection of resistant cells with a commercially available pre-miR precursor to
microRNA-27a, but not microRNA-25 or -32, lowered the expression of SLC7A11 (Fig.
4A) and increased sensitivity by one hundred fold following a 12 μM treatment with
cisplatin (Fig. 4B). This suggests reduced expression of microRNA-27a can induce cisplatin
resistance in bladder cancer cells, by reducing the level of cellular SLC7A11.
Downregulation of microRNA-27a in EJ-R cells was also further confirmed by standalone
qPCR (Supplementary Figure 1). The restoration of cisplatin sensitivity following increased
expression of microRNA-27a was associated with an increase in 1,2 (G,G) intrastrand
adducts following cisplatin treatment (Fig. 4C) and a decrease in intracellular glutathione
(Fig. 4D), supporting the hypothesis that microRNA-27a downregulation protects cells from
the cytotoxic effect of cisplatin via alterations in glutathione biosynthesis. To determine
whether the SLC7A11 3′UTR can be a direct target of microRNA-27a in living cells, we
constructed a luciferase reporter assay using the wild type and a mutant SLC7A11 miR-27
seed sequence. Inhibition of microRNA-27a production in HEK293 cells using a
commercially available inhibitory RNA significantly increased expression of luciferase
reporter augmented with the relevant part of the SLC7A11 3′UTR. This effect was abolished
by mutation of the microRNA-27a seed sequence (Fig. 4E).
The cisplatin sensitivity of a resistant ovarian cancer cell line can also be increased by
modulation of microRNA27a levels
Cisplatin resistance though SLC7A11 was first reported when the drug-resistant ovarian
cancer line A2780-cDDP was found to have higher cystine uptake and intracellular
glutathione concentrations than its cisplatin-sensitive parent (7). Resistance could be
induced with transfection of components of the Xc- transporter (SLC7A11 and SLC3A2).
We transfected A2780-cDDP with pre-miR-27a, and similar to EJ-R cells, transfection
resulted in a tenfold increase in cisplatin sensitivity, suggesting that altered levels of
microRNA-27a can effect cisplatin sensitivity in other cancer types.
SLC7A11 is a key modulator of cisplatin resistance in bladder cancer cells
Evidence of the importance of SLC7A11 in the regulation of cisplatin resistance is
demonstrated by the increased sensitivity of formerly resistant EJ-R cells to cisplatin when
transfected with an siRNA against SLC7A11 (Fig 5A, B). Taken together these data suggest
that direct targeting of the SLC7A11 mRNA 3′UTR by microRNA-27a, alters glutathione
levels in cells, which can then sequester and detoxify cisplatin, resulting in decreased
cisplatin-induced DNA adduct formation and consequently cellular resistance to cisplatin
Inhibition of SLC7A11 with Sulfasalazine, at clinically relevant doses, resensitises
cisplatin-resistant bladder cancer cells
The xc- transporter has recently been implicated as a causative mechanism for seizures in
patients with glioma (24). Specifically, upregulation of Xc- led to high peritumoral
concentrations of glutamate, a neuro-excitatory amino acid that precipitated seizures (25).
Whilst the role of Xc- is unknown in glioma, seizures could be reduced in a model using the
proven Xc inhibitor sulfasalazine (SLZ) (26) at doses equivalent to those used to treat
Crohn’s inflammatory bowel disease (250 μM) in humans (24). We evaluated the potential
for sulfasalazine to induce cisplatin sensitivity in our cells through Xc- inhibition. We found
this dose of sulfasalazine increased the cisplatin sensitivity of resistant cells more than 10-
fold compared to a DMSO control (Fig. 5C).
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microRNA-27a/b expression correlates with increased SLC7A11 expression and poor
prognosis in bladder cancer patients
To examine the clinical significance of our current findings we studied tumors from two
distinct patient cohorts. The first included 139 primary tumors representing the disease
spectrum. While our in vitro data implicate microRNA-27a in cisplatin resistance, its
similarity to microRNA-27b and the fact that both were downregulated in resistant cells,
combined with our previous observation that both are abnormally expressed in primary
bladder cancer (18), lead us to examine the expression of both in this first cohort. We found
that the expression of microRNAs 27a/27b were directly correlated (r=0.75 p>0.001) and
inversely related to SLC7A11 mRNA expression (r=−0.64, p>0.001) (Fig. 6A,
Supplementary Table 1). When outcome was analysed, tumors with high SLC7A11 and/or
low microRNA-27a/27b expression progressed more frequently to advanced disease
following treatment, compared to others (Log rank p<0.04 Fig. 6B). The second cohort
included the tumors from 215 patients treated with chemotherapy as part of a randomized
control trial comparing two cisplatin-based regimens (15) and with gemcitabine-cisplatin.
High membranous expression of SLC7A11 was identified in 22/215 (10.2%) tumors and
was associated with poor cisplatin response (p<0.04, Fig. 6C). In particular, patients whose
tumors had high SLC7A11 protein expression responded to cisplatin less frequently and for
a shorter duration than those with little or no expression. In multivariable analysis,
SLC7A11 expression (HR 2.0 (95% CI 1.1-3.5 p=0.017)) and extent of lymph node
involvement (HR 4.4 (1.1-18.5) p=0.04)) were the only variables independently predicting
progression and cancer-specific survival (Fig. 6D, Supplementary Table 2).
Discussion
Many previous studies have examined alterations in microRNA expression during the
development of cisplatin resistance in various cancer lines including those derived from
hepatocellular carcinoma (27), ovarian cancer (28), non-small cell lung cancer (29), and
germ line tumours (29). None of these studies identified microRNA-27a as a potential
marker for or mediator of cisplatin resistance. The action of specific microRNAs tends to be
highly specific to particular tissues, and consistent with this microRNA-27a has been
reported as having both oncogenic and tumour suppressive roles in various tumours. In
cancer types such as breast (30) and prostate (31) microRNA-27a has been considered an
onco-miR, with high levels of expression being associated with a poor prognosis, whereas in
acute leukemia it has been suggested that microRNA-27a functions as a tumour suppressor
(32). Consistent with our data suggesting microRNA-27a as a key mediator of drug
resistance and prognosis in the context of bladder cancer, a recent paper found
microRNA-27a to be consistently downregulated in fixed formalin paraffin embedded
bladder tumour material from patients who experienced disease progression when compared
to material from those patients who experienced a complete response (33).
MicroRNA-27a forms part of a larger signature of microRNA expression that stratifies
cisplatin resistance in bladder cancer. While many of these microRNAs no doubt have
functional roles in the mediation of cisplatin resistance, we have uncovered a critical role for
microRNA-27a, namely its decreased expression in cisplatin resistant bladder cancer
modulating SLC7A11 upregulation and therefore allowing for increased cystine import and
increased glutathione synthesis. This linked our microRNA signature with well established
and widely studied mechanisms of cisplatin resistance (34).
When designing our experiments we were interested in understanding whether our
mechanism of drug resistance would arise de novo with carcinogenesis (i.e. in cells not
exposed to cisplatin) or be acquired during cisplatin treatment. It is likely that both occur in
cancer, as many hallmarks of carcinogenesis produce drug resistance as a secondary
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phenotype (e.g. apoptosis avoidance). In an attempt to model these different scenarios we
derived drug resistant cells from two different cell populations: heterogeneous cells and
expansions of single cell clones. Whilst resistance in former may reflect the selection of de
novo resistant-cells, the latter models acquired resistance by the conversion of sensitive to
resistant cells. It was interesting to see that our resistance mechanism was common to all
derived cells, regardless of initial population. Indeed, microRNA profiling revealed many
other similarities between the resistant cell lines.
Our findings have direct clinical implications for patient care. Firstly, analysis of tumour
material revealed that microRNA-27a downregulation and associated SLC7A11
upregulation is not unique to a cell culture model of cisplatin resistance and occurs in
tumours in vivo. Secondly, we identified that cisplatin resistance could be reversed by either
re-instatement of the microRNA, by siRNA-induced knockdown of SLC7A11, or by
inhibition of SLC7A11 with a small molecule inhibitor. Since the latter is possible with
clinically achievable doses of sulfasalazine, our findings highlight the need to evaluate this
drug in combination with cisplatin within a clinical trial. Indeed, the side effect profiles of
these agents suggest little cross toxicity, beyond bone marrow suppression. Thirdly, the
expression of microRNA-27a/27b and SLC7A11, or increased intracellular glutathione
within tumors may be used to predict cisplatin response in individual patients. This could
guide chemotherapy choice towards alternative agents not detoxified by glutathione in
tumors likely to be resistant. Recent radiological advances have enabled the spatial and
temporal resolution of glutamate (26) and glutathione (35) in vivo using magnetic resonance
imaging spectroscopy. Our findings suggest that this imaging modality could determine
glutamate concentrations within a tumor and could be used as a surrogate for cisplatin
resistance (36). This approach could inform the initial chemotherapy regimen and monitor
drug resistance before clinical relapse occurs.
In summary, we have identified a novel mechanism of cisplatin resistance in cancer namely
increased expression of mircoRNA-27a mediated regulation of intracellular glutathione. The
direct clinical implications of our work are that this mechanism may be overcome by
clinically achievable doses of sulfasalazine and could be predicted using MRI spectroscopy
to measure tumor glutamate concentrations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Translational Relevance
Cisplatin-based chemotherapy is the first line systemic treatment for advanced bladder
and ovarian cancers. Most patients with these cancers eventually suffer recurrence with
cisplatin-resistant disease. Mechanisms by which resistance is achieved are varied and
better understanding of these is essential for the development of re-sensitization
strategies. We found consistent dysregulation of a panel of microRNAs during the
development of cisplatin resistance in bladder cancer, and showed that one of these
microRNAs (microRNA-27a) targets a cystine/glutamate exchanger, which mediates
glutathione synthesis SLC7A11. Cancer samples from patients showed dysregulation of
these molecules stratified clinical outcomes in patients treated with cisplatin. Cisplatin
resistance in our cells could be reversed using siRNA to the target genes and
sulfasalazine, a FDA approved drug known to inhibit SLC7A11.
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Figure 1. Characterization of cisplatin resistant cell lines and microRNA expression
(a) Clonogenic survival assays of cisplatin-treated bladder cancer cell lines and their
cisplatin-resistant derivatives (designated as respective cell line followed by R). Error bars
indicate SD, n=4 (b) Fold change in expression of c. 160 microRNAs in three paired
sensitive and resistant lines. (c) Hierarchical clustering using 32 selected miRs (red = low
expression, green = high expression) stratifies cells according to cisplatin resistance (orange
– resistant, white – sensitive) regardless of cell line or method of derivation.
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Figure 2. Genotoxicty of cisplatin and measurement of cisplatin/DNA adducts in sensitive and
resistant cells
(a) Measurement of 1,2 (G,G) Intrastrand Cisplatin-DNA adducts in genomic DNA of EJ
and EJ-R cells following a two hour treatment with a range of cisplatin concentrations. Error
bars indicate SD, n=3. p<0.001 for all concentrations of cisplatin above 1 μM (b)
Densitromic plot of extent of 1,2 (G,G) Intrastrand Cisplatin-DNA adduct repair in EJ / EJ-
R for 48 hours following a two hour treatment with 12 μM cisplatin. Error bars indicate SD,
n=3 (c) Example dot blot used to generate data visualized in Fig 3B.
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Fig 3. Analysis of candidate pathways mediating cisplatin resistance in sensitive and resistant
cells
(a) Change in expression of three mRNAs concerned with cisplatin import (CTR1) and
export (ATP7A, ATP7B) in three paired cisplatin sensitive (EJ, D4, G7) and resistant (EJ-R,
D4-R, G7-R) cell lines. (b) Measurement of intracellular glutathione (Reduced glutathione/
GSH – black bars, Total glutathione GSH and GSSG, white bars) in EJ bladder cancer cells
and their cisplatin-resistant derivative line EJ. Error bars indicate SD, n=3, * p<0.01
**p<0.0005. (c) Change in expression of six mRNAs concerned with glutathione
biosynthesis in three paired cisplatin sensitive (EJ, D4, G7) and resistant (EJ-R, D4-R, G7-
R) cell lines. (d) Western blot of proteins concerned with cisplatin import and export
(ATP7A (163 kDa), CTR1 (35 kDa), SLC7A11 (55 kDa) against α-tubulin (55kDa)) in
three paired cisplatin sensitive (EJ, D4, G7) and resistant (EJ-R, D4-R, G7-R) cell lines.
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Figure 4. Effect of microRNA-27a manipulation on SLC7A11 expression, cisplatin sensitivity
and cisplatin genotoxicity in resistant bladder and ovarian cancer cells
(a) Western blot of SLC7A11 expression following transfection of cisplatin-resistant cells
with microRNA-27a, microRNA-25 or microRNA-32, (mIR-27a, -25, -32). (b) Effect of
increased microRNA-27a expression on cisplatin sensitivity of EJ-R cells compared to a
scrambled control oligo as measured by clonogenic assay. Error bars indicate SD, n=3 (c)
Effect of increased microRNA-27a expression of level of cisplatin induced DNA damage in
EJ-R cells compared to untreated and scrambled RNA controls. Error bars indicate SD, n=3
(d) Effect of increased microRNA-27a expression on levels of reduced (black bars) and total
(white bars) glutathione *= p<0.01. Error bars indicate SD, n=3 (e) Effect on luciferase
expression of a microRNA-27a inhibitor in HEK293 cells compared to scrambled control .
The luciferase gene was augmented with a portion of the 3′UTR of SLC7A11 containing the
microRNA-27a binding site, or a similar construct with the microRNA-27a abolished by
site-directed mutagenesis (mutant). (f) Effect of increased microRNA-27a expression
(miR-27a) or transfection with a scrambled control (Scrm) on cisplatin sensitivity the
cisplatin resistant ovarian cancer cell line A2780-cDDP as measured by clonogenic assay.
Error bars indicate SD, n=3
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Figure 5. Effect of SLC7A11 knockdown and inhibition on cisplatin sensitivity
(a) Use of siRNA directed against SLC7A11 to reduce SLC7A11 protein levels in EJ-R cells
48 hours post transfection. (b) Effect of SLC7A11 knockdown compared with scrambled
RNA control on cisplatin sensitivity of EJR cells as measured by clonogenic assay. Error
bars indicate SD, n=3. *** = p<0.005 (e) Effect of sulfasalazine pretreatment on cisplatin
sensitivity of EJ-R cells as measured by clonogenic assay. Error bars indicate SD, n=3 *
p<0.1
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Fig 6. Clinical significance of decreased miR-27a/b expression and increased SLC7A11
expression in bladder tumours
(a) Expression of miR-27a/27b and SLC7A11 mRNA in bladder cancer samples as
determined by real-time PCR. (b). Correlation between low microRNA-27a expression (red
line) and an aggressive tumor phenotype as shown by progression to invasion and
metastases following treatment in 139 freshly frozen tumors. (c). High membranous
SLC7A11 protein expression was identified in 10.5% of tumors (examples shown of high
(100x and 630x) and absent expression (630x)) in a tissue array of tumors from patients
treated with adjuvant chemotherapy for invasive bladder cancer. (d) SLC7A11 protein
expression stratifies progression free and cancer specific survival (CSS) in patients treated
with this agent within an RCT of cisplatin-based regimens. (*P<0.05, ** P<0.001)
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